XML 25 R14.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Balance Sheet Details | 3 Months Ended
--- | ---
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Balance Sheet Details | 5. Balance Sheet Details Inventory consisted of the following (in thousands):
|  | March 31, 2024 |  |  | December 31, 2023 |
Finished goods |  | $ | 7,576 |  |  | $ | 5,001 |
Work in process |  |  | 5,549 |  |  |  | 4,134 |
Raw material |  |  | 53,518 |  |  |  | 31,312 |
|  | $ | 66,643 |  |  | $ | 40,447 |
Reported as: |  |  |  |  |  |
Inventory |  | $ | 61,936 |  |  | $ | 35,819 |
Long-term inventory |  |  | 4,707 |  |  |  | 4,628 |
Total |  | $ | 66,643 |  |  | $ | 40,447 |
Amount reported as long-term inventory consisted of raw materials as of March 31, 2024 and December 31, 2023. The Company has raw materials beyond a one year production plan that help limit the exposures from potential supply interruption. Those raw materials beyond the one year production plan were classified as long-term inventory. Accrued liabilities consisted of the following (in thousands):
|  | March 31, 2024 |  |  | December 31, 2023 |
Accrued sales allowances |  | $ | 122,436 |  |  | $ | 90,718 |
Accrued contingent payments |  |  | 79,583 |  |  |  | 29,583 |
Accrued compensation and benefits |  |  | 26,061 |  |  |  | 42,718 |
Accrued research and development services |  |  | 23,878 |  |  |  | 32,883 |
Accrued consulting and professional fees |  |  | 19,684 |  |  |  | 18,804 |
Current portion of lease liabilities |  |  | 10,453 |  |  |  | 9,405 |
Current portion of accrued branded prescription drug fees |  |  | 7,836 |  |  |  | 718 |
Accrued royalties |  |  | 7,591 |  |  |  | 8,710 |
Other |  |  | 13,743 |  |  |  | 3,172 |
|  | $ | 311,265 |  |  | $ | 236,711 |

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//210/tableOfContent + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration